139 related articles for article (PubMed ID: 36449115)
1. Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition.
Sueyoshi R; Furuhashi N; Ishii J; Yamaguchi R; Kawakami M; Tanabe K; Segawa O
Pediatr Surg Int; 2022 Nov; 39(1):21. PubMed ID: 36449115
[TBL] [Abstract][Full Text] [Related]
2. Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome.
Yano K; Kaji T; Onishi S; Machigashira S; Nagai T; Harumatsu T; Yamada K; Yamada W; Muto M; Nakame K; Mukai M; Ieiri S
Pediatr Surg Int; 2019 Dec; 35(12):1345-1351. PubMed ID: 31555865
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model.
Sueyoshi R; Woods Ignatoski KM; Okawada M; Hartmann B; Holst J; Teitelbaum DH
Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(4):G410-9. PubMed ID: 24970775
[TBL] [Abstract][Full Text] [Related]
4. DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome.
Sueyoshi R; Miyahara K; Nakazawa-Tanaka N; Fujiwara N; Ochi T; Yamataka A
Pediatr Surg Int; 2020 Jan; 36(1):49-55. PubMed ID: 31576468
[TBL] [Abstract][Full Text] [Related]
5. The preventive effect of recombinant human hepatocyte growth factor for hepatic steatosis in a rat model of short bowel syndrome.
Yano K; Sugita K; Muto M; Matsukubo M; Onishi S; Kedoin C; Matsui M; Murakami M; Harumatsu T; Yamada K; Yamada W; Kumagai K; Ido A; Kaji T; Ieiri S
J Pediatr Surg; 2022 Jul; 57(7):1286-1292. PubMed ID: 35396090
[TBL] [Abstract][Full Text] [Related]
6. Synergy of glucagon-like peptide-2 and epidermal growth factor coadministration on intestinal adaptation in neonatal piglets with short bowel syndrome.
Lim DW; Levesque CL; Vine DF; Muto M; Koepke JR; Nation PN; Wizzard PR; Li J; Bigam DL; Brubaker PL; Turner JM; Wales PW
Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G390-G404. PubMed ID: 28104586
[TBL] [Abstract][Full Text] [Related]
7. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression.
Lee M; Shin E; Bae J; Cho Y; Lee JY; Lee YH; Lee BW; Kang ES; Cha BS
Sci Rep; 2020 Nov; 10(1):19429. PubMed ID: 33173107
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
10. Histopathological liver steatosis linked with high parenteral glucose and amino acid supply in infants with short bowel syndrome.
Gunnar R; Mutanen A; Merras-Salmio L; Pakarinen MP
JPEN J Parenter Enteral Nutr; 2023 Jan; 47(1):41-50. PubMed ID: 35633305
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis.
Hu X; Cheng W; Fan S; Huang Y; Chen X; Jiang Z; Wang J
BMC Infect Dis; 2021 Jun; 21(1):583. PubMed ID: 34134659
[TBL] [Abstract][Full Text] [Related]
12. Effect of alpha-naphthylisothiocyanate-induced liver injury on intestinal adaptation in a rat model of short bowel syndrome.
Sukhotnik I; Razon H; Pollak Y; Hayari L; Bejar J; Mogilner JG; Sylvester KG
Pediatr Surg Int; 2012 Feb; 28(2):161-9. PubMed ID: 21989949
[TBL] [Abstract][Full Text] [Related]
13. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.
Naimi RM; Hvistendahl MK; Thomassen LM; Johnsen H; Christiansen CB; Holst JJ; Hartmann B; Jeppesen PB
BMJ Open Gastroenterol; 2021 May; 8(1):. PubMed ID: 33975891
[TBL] [Abstract][Full Text] [Related]
15. Bilirubin impairs intestinal regrowth following massive small bowel resection in a rat model.
Sukhotnik I; Shaoul R; Lieber M; Coran AG; Abassi Z; Shiloni E; Mogilner JG
J Pediatr Gastroenterol Nutr; 2009 Jul; 49(1):16-22. PubMed ID: 19465868
[TBL] [Abstract][Full Text] [Related]
16. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.
Okawada M; Holst JJ; Teitelbaum DH
Surgery; 2011 Aug; 150(2):217-23. PubMed ID: 21719060
[TBL] [Abstract][Full Text] [Related]
17. The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome.
Onishi S; Kaji T; Yamada W; Nakame K; Moriguchi T; Sugita K; Yamada K; Kawano T; Mukai M; Souda M; Yamada S; Yoshioka T; Tanimoto A; Ieiri S
Pediatr Surg Int; 2016 Dec; 32(12):1165-1171. PubMed ID: 27651372
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis.
Ben-Shlomo S; Zvibel I; Rabinowich L; Goldiner I; Shlomai A; Santo EM; Halpern Z; Oren R; Fishman S
Dig Dis Sci; 2013 Jan; 58(1):172-8. PubMed ID: 22918684
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study.
Madsen KB; Askov-Hansen C; Naimi RM; Brandt CF; Hartmann B; Holst JJ; Mortensen PB; Jeppesen PB
Regul Pept; 2013 Jun; 184():30-9. PubMed ID: 23511332
[TBL] [Abstract][Full Text] [Related]
20. Effect of subcutaneous insulin on intestinal adaptation in a rat model of short bowel syndrome.
Sukhotnik I; Mogilner J; Shamir R; Shehadeh N; Bejar J; Hirsh M; Coran AG
Pediatr Surg Int; 2005 Mar; 21(3):132-7. PubMed ID: 15756562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
